Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0372 • ACR Convergence 2020
Tumor Necrosis Factor-α Receptor 2 Polymorphisms and Response to TNF Inhibitor Therapy in Patients with Psoriatic Arthritis
Sarah Rasheed¹, MacKenzie Dunlap¹, Jennifer Harvey¹, Connery Brennan¹, Yuxuan Jin², Unnikrishnan Chandrasekharan³ and M. Elaine Husni², ¹Cleveland Clinic Foundation, Cleveland, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have significantly improved the prognosis of patients with psoriatic arthritis (PsA); however, approximately 40% of patients do not achieve…
Abstract Number: 0507 • ACR Convergence 2020
Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study
Grace Wright¹, Peter Nash², Laura Coates³, Jordi Gratacós⁴, Frank Behrens⁵, Kevin Ding⁶, Weibin Bao⁷, Luminita Pricop⁶, Corine Gaillez⁸ and Iain McInnes⁹, ¹Association of Women in Rheumatology, New York, NY, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Oxford, Oxford, United Kingdom, ⁴University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁵CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁶Novartis Pharmaceuticals Corporation, East Hanover, ⁷Novartis Pharmaceuticals Corporation, East Hannover, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries.1…
Abstract Number: 0896 • ACR Convergence 2020
Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs
Iain McInnes¹, William Tillett², Philip Mease³, Kurt de Vlam⁴, Louis Bessette⁵, Ralph Lippe⁶, Anna Maniccia⁷, Patrick Zueger⁷, Dai Feng⁷, Koji Kato⁸ and Andrew Östör⁹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ⁵Laval University, Quebec, Canada, ⁶AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc, North Chicago, IL, ⁹Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…
Abstract Number: 1230 • ACR Convergence 2020
Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis
Neha Bhaskar¹, Lilian Otalora Rojas², Tara Jehu¹, Shazia Beg¹ and Neha Bhanusali¹, ¹University of Central Florida College of Medicine, orlando, ²University of Central Florida HCA Healthcare GME, Orlando
Background/Purpose: Ancient Eastern medicine has valued the Curcuma longa (turmeric) plant for its powerful medicinal properties. Curcumin is suggested to possess potent anti-inflammatory, antioxidant, antimicrobial,…
Abstract Number: 1349 • ACR Convergence 2020
Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Laura Coates¹, Christopher Ritchlin², Laure Gossec³, Philip Helliwell⁴, Proton Rahman⁵, Elizabeth Hsia⁶, Alexa Kollmeier⁷, Xie Xu⁸, Chetan Karyekar⁹, May Shawi¹⁰, Wim Noël¹¹, Yusang Jiang¹², Shihong Sheng¹², Prasheen Agarwal¹² and Philip Mease¹³, ¹University of Oxford, Oxford, United Kingdom, ²Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁶Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC, San Marcos, CA, ⁹Janssen Global Services, LLC, Horsham, PA, ¹⁰Janssen Global Services, LLC, Toronto, ON, Canada, ¹¹Janssen Medical Affairs, LLC, Beerse, Belgium, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody that specifically binds to the p19-subunit of IL-23. GUS has demonstrated efficacy across the various manifestations of…
Abstract Number: 1476 • ACR Convergence 2020
Trends in Mortality and Cause-specific Mortality Among Patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada
Keith Colaco¹, Jessica Widdifield², Jin Luo³, Cheryl Rosen⁴, Raed Alhusayen⁵, J. Michael Paterson⁶, Willemina Campbell⁷, Karen Tu⁴, Sasha Bernatsky⁸, Dafna Gladman⁹ and Lihi Eder¹⁰, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³ICES, Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, ⁶ICES, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, ON, Canada, ⁸The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ⁹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁰Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Several studies have consistently demonstrated that psoriasis is associated with an increased risk of mortality compared to the general population. However, the excess risk…
Abstract Number: 1860 • ACR Convergence 2020
An Integrative Approach to Identify Heritable and De Novo Genomic Variations in Psoriatic Arthritis Mutilans and Understand Its Systems Biology
Sara Rahmati¹, Quan Li¹, Dafna Gladman², Proton Rahman³ and Vinod Chandran², ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada
Background/Purpose: Psoriasis is a chronic autoimmune skin disease that burdens ~3% of North Americans. ~24% of psoriatic patients develop psoriasis arthritis (PsA), an inflammatory disease…
Abstract Number: 0102 • ACR Convergence 2020
Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study
Diana Camelia Dan¹, Youssef Ibrahimy², Berengere Aubry-Rozier³ and Daniel Aeberli⁴, ¹Lausanne University Hospital, Lausanne, Switzerland, ²University of Lausanne, Lausanne, Switzerland, ³Hôpital orthopédique, Lausanne, Switzerland, ⁴University Hospital of Bern, Bern, Switzerland
Background/Purpose: There is much controversy surrounding the loss of bone mass in patients with psoriasis arthritis (PsA). We wanted to evaluate the prevalence of osteoporosis…
Abstract Number: 0312 • ACR Convergence 2020
Dactylitis Is Associated with Greater Disease Severity, Ultrasound Synovitis, and Erosive Damage, in Very Early DMARD Naïve Psoriatic Arthritis
Sayam Dubash¹, Oras Alabas², Xabier Michelena², Gabriele De Marco³, Leticia Garcia-Montoya², Richard Wakefield², Ai Lyn Tan², Philip Helliwell⁴, Paul Emery⁵, Dennis McGonagle² and Helena Marzo-Ortega², ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, England, United Kingdom, ²The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Treviglio, Italy, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Dactylitis is a hallmark feature of Psoriatic arthritis (PsA), defined as a uniform swelling of a finger or toe (“sausage digit”). It is associated…
Abstract Number: 0328 • ACR Convergence 2020
Healthcare Utilization and Costs Among Patients with Psoriatic Arthritis and Psoriasis in the United States – a Retrospective Study of Claims Data from 2009 to 2020
Joseph Merola¹, Reginald Villacorta², Natalie Dennis³, Soumya Chakravarty⁴, Laura Mesana⁵, Iris Lin², Maud Pacou³, Thomas Baker⁶, Yiting Wang⁷ and Steven Peterson⁸, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Janssen Immunology Global Commercial Strategy Organization, Horsham, ³Amaris, Paris, France, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁵Amaris, New York, ⁶Janssen Global Services, LLC, Raritan, NJ, ⁷Janssen R&D, LLC, Titusville, ⁸Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: The costs of psoriasis and psoriatic arthritis (PsA) are substantial for both patients and the United States healthcare system. This study compared healthcare resource…
Abstract Number: 0346 • ACR Convergence 2020
Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
Philip Mease¹, Josef Smolen², Arthur Kavanaugh³, Peter Nash⁴, Gaia Gallo⁵, Soyi Liu-Leage⁵, Christophe Sapin⁵ and Mark Genovese⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ³UC San Diego Health System, San Diego, CA, ⁴School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Ixekizumab (IXE) was shown to be superior to adalimumab (ADA) in achievement of simultaneous improvement of joint and skin disease (American college of Rheumatology…
Abstract Number: 0374 • ACR Convergence 2020
Neo-epitopes of Type I Collagen Can Be Utilized as Translational Biomarkers for Skin and Joint Turnover in Patients with Psoriasis and Psoriatic Arthritis
Solveig S. Groen¹, Signe Holm Nielsen², Conor Magee³, Anne Sofie Siebuhr⁴, Anne C. Bay-Jensen², Morten A. Karsdal⁴, Stephen Pennington⁵ and Oliver FitzGerald⁶, ¹University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³St Vincent's University Hospital and the UCD Conway Institute, University College Dublin, Dublin, Ireland, ⁴Nordic Bioscience A/S, Herlev, Denmark, ⁵University College Dublin, Dublin, Dublin, Ireland, ⁶Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
Background/Purpose: Psoriasis (PsO) is a chronic immune-mediated skin disease. Around 30% of patients diagnosed with PsO will develop psoriatic arthritis (PsA). Patients with PsA may…
Abstract Number: 0508 • ACR Convergence 2020
Maintenance or Achievement of Minimal Disease Activity Following Therapy Optimization with Adalimumab or Methotrexate in Patients with Psoriatic Arthritis: Results from Part 2 of a Randomized, Open-Label Phase 4 Study
Philip Mease¹, Philip G Conaghan², William Tillett³, Maria Antonietta D'Agostino⁴, Proton Rahman⁵, Frank Behrens⁶, Erin Blondell⁷, Xianwei Bu⁸, Liang Chen⁷, Mudra Kapoor⁸ and Laura Coates⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, ³Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁴Paris-Saclay Versailles University, Hôpital Ambroise Paré, Boulogne-Billancourt, France, ⁵Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁶CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie, North Chicago, IL, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Minimal Disease Activity (MDA) is suggested as an appropriate treat-to-target outcome for patients (pts) with PsA. Results from Part 1 of the CONTROL study…
Abstract Number: 0898 • ACR Convergence 2020
Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy in a Real-world US Commercially Insured Population
Julie Birt¹, Michael Grabner², Keith Isenberg³, Theresa Hunter⁴, Chia-Chen Teng², Mingyang Shan¹, Jeffrey Lisse¹, Jianmin Wu¹, Kirstin Griffing¹ and Jeffrey R Curtis⁵, ¹Eli Lilly and Company, Indianapolis, IN, ²Healthcore, Inc, Wilmington, DE, ³Anthem, Inc, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year associated with advanced therapy (AT) initiation among…
Abstract Number: 1311 • ACR Convergence 2020
Identification of Clinical Phenotypes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis According to Peripheral Musculoskeletal Manifestations: A Cluster Analysis in the International ASAS-PerSpA Study
Clementina Lopez-Medina¹, Sylvie Chevret², Anna Molto¹, Joachim Sieper³, Mehmet Tuncay Duruöz⁴, Uta Kiltz⁵, Bassel El-Zorkany⁶, Najia Hajjaj-Hassouni⁷, Ruben Burgos-Vargas⁸, Jose Maldonado-Cocco⁹, Nelly Ziade¹⁰, Meghna Gavali¹¹, Victoria Navarro-Compán¹², Shue Fen Luo¹³, Alessandro Biglia¹⁴, Tae-Jong Kim¹⁵, Mitsumasa Kishimoto¹⁶, Fernando Pimentel-Santos¹⁷, Jieruo Gu¹⁸, Laura Muntean¹⁹, Floris van Gaalen²⁰, Pál Géher²¹, Marina Magrey²², Sebastian Ibanez²³, Wilson Bautista-Molano²⁴, Walter Maksymowych²⁵, Pedro M Machado²⁶, Robert Landewé²⁷, Désirée van der Heijde²⁸ and Maxime Dougados²⁹, ¹Rheumatology Department, Cochin Hospital, Paris, Paris, France, ²INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey, ⁵Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁶Cairo University, Cairo, Egypt, ⁷Health Sciences College, International University of Rabat (UIR), Rabat, Morocco, ⁸Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ⁹Buenos Aires School of Medicine, Buenos Aires, Argentina, ¹⁰Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ¹¹Nizam’s Institute of Medical Sciences, Hyderabad, India, ¹²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ¹³Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ¹⁴Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ¹⁵Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ¹⁶Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁷3.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisbon, Portugal, ¹⁸Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, guangzhou, China (People's Republic), ¹⁹Rheumatology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, ²⁰Leiden University Medical Center (LUMC), Leiden, Netherlands, ²¹Semmelweis University, Budapest, Budapest, Hungary, ²²Case Western Reserve University School of Medicine, Cleveland, OH, ²³Facultad de Medicina Clínica Alemana – Universidad del Desarrollo, Santiago, Region Metropolitana, Chile, ²⁴University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia, ²⁵University of Alberta, Edmonton, AB, Canada, ²⁶University College London, London, United Kingdom, ²⁷Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ²⁸Leiden University Medical Center, Leiden, Netherlands, ²⁹Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France
Background/Purpose: Patients with a clinical diagnosis of Spondyloarthritis (SpA) and Psoriatic Arthritis (PsA) may have predominant axial or predominant peripheral symptoms. However, a huge clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].